Future Perspectives: A Review of Therapeutic Advances in Recurrent Glioblastoma

Abstract

The outcomes for glioblastoma (GBM) patients remain dismal despite significant increases in our understanding of treatment-naïve disease biology and increased focus on clinical trials. Almost all patients experience disease recurrence. If we hope to develop more durable responses in this aggressive disease cohort, a better understanding of resistance mechanisms and drivers of GBM tumour recurrence will be needed. Here we review the findings to-date of current advances in therapeutic development and biology of recurrent GBM, highlighting recent research and clinical trials breakthroughs.